commercialized CD19 CAR-T cells

**Commercialized CD19 CAR-T cells** refers to autologous or allogeneic T cells genetically engineered to express a chimeric antigen receptor (CAR) targeting the B-lymphocyte antigen CD19, which have received regulatory approval and are commercially available (such as axicabtagene ciloleucel or tisagenlecleucel). These therapies are designed to bind to CD19-expressing normal and malignant B cells, leading to T-cell activation, cytokine release, and target cell lysis. They are primarily used for the treatment of refractory or relapsed B-cell malignancies, including non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), and transformed follicular lymphoma (TFL). In clinical trial settings, such as those sponsored by Henan Province Cancer Hospital, commercialized CD19 CAR-T cells are evaluated for safety and efficacy in specific patient cohorts.

Other names

commercialized CD19 CAR-Tcommercialized CD19 CAR-T cell therapy